Transgene Biotek jumps 5% on tie-up with Portugal-based firm

Transgene Biotek climbed on Wednesday after it entered into a definitive licensing and technology transfer agreement with Atral Cipan of Portugal. The agreement provides the basis for the manufacture and making infrastructure, commercialization and marketing of the immune-suppressant drug Tacrolimus using technology developed and transferred by Transgene Biotek. Shares ofthe companyare trading at Rs 3.71, up Rs 0.17, or 4.80% at the Bombay Stock Exchange (BSE) on Wednesday at 2:10 p.m.The scrip has touched an intra-day high of Rs 3.71 and low of Rs 3.37. The total volume of shares traded at the BSE is 494,466.In the earlier session, the shares declined 4.84%, or Rs 0.18, at Rs 3.54. Currently, the stock is trading down 90.86% from its 52-week high of Rs 40.60 and above 4.8% over the 52-week low of Rs 3.54.

Share Price Movement Period Pricein Rs Gain/(Loss) in Rs in % 1 Week 4.06 (0.52) (12.81) 1 Month 4.18 (0.64) (15.31) 3 Months 7.46 (3.92) (52.55) 6 Months 9.70 (6.16) (63.51) 1 Year 28.90 (25.36) (87.75) Note: Based on previous day closing price.